The NICE has advised using semaglutide combined with a low-calorie diet and exercise. Thousands of patients will get access to a weight-loss medication provided by the NHS as part of broader patient therapy. When combined with the assistance of an NHS multidisciplinary team, the treatment will assist those who utilize it in losing more than 10% of their body weight. These experts monitor potential pharmacological adverse effects while also advising clients on lifestyle changes.
Evidence from clinical trials shows that semaglutide combined with supervised weight loss coaching results in more weight loss than assistance alone. Upon the producer of the medication, Novo Nordisk, launching it, NHS patients will have access to it.
READ ON: A Recipe For Chocolate-Chip Cookies
In the meantime, persons with a body mass index (BMI) of at least 35 kg/m2 or who have at least one weight-related comorbidity are advised to take semaglutide, also known as Wegovy, together with a reduced-calorie diet and increased physical exercise.
Moreover, patients who qualify for referral to specialized weight management services and have a BMI between 30 and 34.9 kg/m2 and one weight-related condition may also have access to the medication.
Dysglycemia, hypertension, dyslipidaemia—where increases in blood lipid concentrations are caused by disruptions in fat metabolism—obstructive sleep apnoea, and cardiovascular disease are among the qualifying conditions.
A professional weight management service offering interdisciplinary care of weight or obesity may only prescribe semaglutide for a maximum of two years. Patients administer the medication by injecting themselves once each week with semaglutide-filled pens.
“For some people, reducing weight is a genuine difficulty, which is why a prescription like semaglutide is a welcome choice,” said Helen Knight, director of medicines evaluation at NICE. Not everyone will be able to access it. It may only be used for a maximum of two years, and our committee has made specific recommendations to make sure the taxpayers are getting value for their money.
“We are glad to finally publish our final guideline on semaglutide,” she continued, “which will allow some individuals to obtain this widely discussed medication on the NHS.
